Comparison of Aptima and hybrid capture‐2 HPV tests and Pap test in the referral population in Japan
- 25 February 2021
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 93 (8) , 5076-5083
Abstract
The Aptima human papillomavirus (HPV) test (APTIMA) detects E6‐E7 mRNA in abnormal cells in the uterine cervix. To investigate the accuracy of APTIMA for cervical cancer screening in Japan, 423 subjects, mostly referrals with abnormal cytology or being followed up for cervical intraepithelial neoplasia (CIN)1, were screened using two HPV tests, hybrid capture 2 (HC2) and APTIMA, and by the Pap test. Colposcopy was conducted in all subjects with a positive result in either test type. HPV genotyping was performed by Genosearch‐31.A result of atypical squamous cells‐undetermined significance (ASC‐US) or worse on the HC2 test (ASC‐US‐HC2), and low‐grade squamous intraepithelial lesion (LSIL) or worse (LSIL+) on the Pap test, was regarded as positive. APTIMA (97.5%) was more sensitive than LSIL+ (85.1%) for detecting CIN2 or worse (CIN2+) (McNemar test; p = .0003), and more sensitive (98.6%) than ASC‐US‐HC2 (92.7%) for detecting CIN3+. APTIMA and HC2 had similar sensitivities. HPV genotyping revealed that CIN2/3 with high‐risk HPV (HR‐HPV) was overlooked in five cases by ASC‐US‐HC2, and in four cases by HC2, while no such lesions were missed by APTIMA. Thus, APTIMA might be superior to HC2 for primary HPV screening in Japan. One cancer case positive for HPV67 (potentially high risk, [pHR]) was overlooked by Pap test and both HPV tests, suggesting a need for a new HPV test able to detect pHR‐HPV types.Keywords
This publication has 29 references indexed in Scilit:
- Clinical Impact of the Analytical Specificity of the Hybrid Capture 2 Test: Data from the New Technologies for Cervical Cancer (NTCC) StudyJournal of Clinical Microbiology, 2013
- Reduced cervical cancer incidence and mortality in Canada: national data from 1932 to 2006BMC Public Health, 2012
- Analytical Comparison of the cobas HPV Test with Hybrid Capture 2 for the Detection of High-Risk HPV GenotypesThe Journal of Molecular Diagnostics, 2012
- Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trialThe Lancet Oncology, 2012
- A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: Extended follow up in the ARTISTIC trialEuropean Journal of Cancer, 2011
- Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide studyThe Lancet Oncology, 2010
- Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trialThe Lancet Oncology, 2010
- Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and olderInternational Journal of Cancer, 2008
- Human Papillomavirus and Papanicolaou Tests to Screen for Cervical CancerNew England Journal of Medicine, 2007
- Management of women who test positive for high-risk types of human papillomavirus: the HART studyThe Lancet, 2003